Stock RICH LABORATORIOS RICHMOND S.A.C.I.F.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Laboratorios Richmond S.A.C.I.F.

Equities

RICH

ARLRIC300027

Pharmaceuticals

End-of-day quote Buenos Aires S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
879 ARS +1.91% Intraday chart for Laboratorios Richmond S.A.C.I.F. +0.51% +25.84%
Mar. 11 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,931 9,367 9,327 17,927 31,412 56,405
Enterprise Value (EV) 1 2,852 9,720 10,516 22,242 50,309 149,735
P/E ratio -13.6 x 80.6 x 19.2 x 30.3 x 193 x -5.2 x
Yield - - 0.48% - - -
Capitalization / Revenue 1.61 x 2.4 x 1.51 x 1.08 x 1.7 x 1.45 x
EV / Revenue 1.57 x 2.5 x 1.7 x 1.34 x 2.72 x 3.84 x
EV / EBITDA 18.8 x 11.3 x 6.66 x 8.95 x 15.1 x 23.2 x
EV / FCF -16.9 x -375 x -27.8 x -9.98 x -5.19 x 58 x
FCF Yield -5.91% -0.27% -3.59% -10% -19.3% 1.72%
Price to Book 2.79 x 4.57 x 2.76 x 3.39 x 3.11 x 2.5 x
Nbr of stocks (in thousands) 80,751 80,751 80,751 80,751 80,751 80,751
Reference price 2 36.30 116.0 115.5 222.0 389.0 698.5
Announcement Date 3/11/19 3/6/20 3/10/21 3/9/22 3/9/23 3/11/24
1ARS in Million2ARS
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,817 3,895 6,181 16,616 18,470 39,028
EBITDA 1 151.7 860.2 1,578 2,486 3,326 6,441
EBIT 1 107.8 780.7 1,487 2,322 2,982 5,299
Operating Margin 5.93% 20.04% 24.06% 13.98% 16.15% 13.58%
Earnings before Tax (EBT) 1 -209.2 210.3 757.7 1,417 799.5 -13,924
Net income 1 -215.6 116.4 486.2 591.5 163.4 -10,851
Net margin -11.87% 2.99% 7.87% 3.56% 0.88% -27.8%
EPS 2 -2.670 1.440 6.020 7.320 2.020 -134.4
Free Cash Flow 1 -168.6 -25.95 -378 -2,228 -9,689 2,579
FCF margin -9.28% -0.67% -6.11% -13.41% -52.46% 6.61%
FCF Conversion (EBITDA) - - - - - 40.05%
FCF Conversion (Net income) - - - - - -
Dividend per Share - - 0.5547 - - -
Announcement Date 3/11/19 3/6/20 3/10/21 3/9/22 3/9/23 3/11/24
1ARS in Million2ARS
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 353 1,189 4,315 18,897 93,330
Net Cash position 1 79.4 - - - - -
Leverage (Debt/EBITDA) - 0.4105 x 0.7536 x 1.736 x 5.681 x 14.49 x
Free Cash Flow 1 -169 -26 -378 -2,228 -9,689 2,579
ROE (net income / shareholders' equity) -19% 6.59% 15.4% 11.4% 1.54% -39.9%
ROA (Net income/ Total Assets) 2.55% 10.5% 11.9% 7.51% 4.11% 2.35%
Assets 1 -8,455 1,109 4,069 7,871 3,979 -461,505
Book Value Per Share 2 13.00 25.40 41.90 65.60 125.0 279.0
Cash Flow per Share 2 6.210 2.690 6.350 57.80 15.60 7.890
Capex 1 159 278 372 5,297 6,688 9,404
Capex / Sales 8.72% 7.14% 6.02% 31.88% 36.21% 24.09%
Announcement Date 3/11/19 3/6/20 3/10/21 3/9/22 3/9/23 3/11/24
1ARS in Million2ARS
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
LABORATORIOS RICHMOND S.A.C.I.F. Stock Laboratorios Richmond S.A.C.I.F.
+25.84% 81.16M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. RICH Stock
  4. Financials Laboratorios Richmond S.A.C.I.F.